Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

20065,081 citationsJournal Articlebronze Open Access

Authors

James A. Bonner · University of Alabama at Birmingham

Paul M. Harari · University of Wisconsin–Madison

J. Giralt · Hebron University

N. Azarnia · Merck (Germany)

Dong M. Shin · The University of Texas MD Anderson Cancer Center

Roger B. Cohen · University of Virginia

Christopher U. Jones

Abstract

Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoregional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head and neck. (ClinicalTrials.gov number, NCT00004227.)

Topics & Keywords

Head and Neck Cancer Studies Lung Cancer Treatments and Mutations Salivary Gland Tumors Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 354, Issue 6, pp. 567-578

DOI: 10.1056/nejmoa053422

Field-Weighted Citation Impact: 298.67